This paper applies Porter's Five Forces framework to the pharmaceutical industry, examining how each competitive force shapes pricing, profitability, and market behavior. It covers supplier power during a drug's initial market period, the threat of substitute drugs once generics emerge, buyer power as alternatives proliferate, rivalry that drives prices toward zero, and barriers to entry that established companies use to protect profitability. The paper also addresses the relationship between pharmaceutical companies, pharmacy benefit managers (PBMs), and physicians, highlighting the ethical and legal constraints that govern how drug companies may influence prescribing behavior.
The paper demonstrates structured framework application: each force is introduced, defined in general terms, and then interpreted specifically within the pharmaceutical context. This technique shows readers how to use a theoretical model as an analytical lens rather than simply describing the model in the abstract.
The paper opens with a brief industry overview, then devotes a focused passage to each of the five forces in sequence. It closes with an extended discussion of the PBM–physician relationship and the ethical constraints on pharmaceutical marketing, tying competitive pressures back to patient welfare. This structure mirrors a classic framework-application essay: introduce the tool, apply each component, then synthesize implications.
Pharmaceutical companies spend many years and millions of dollars developing new drugs. In order to be successful, these companies must sell any successful drug at a high price to recoup development costs. Once other companies replicate the drug, competition drives its price down. Most consumers use insurance companies to pay for their prescriptions through pharmacy benefit management (PBM) programs. Pharmaceutical companies attempt to negotiate deals with PBMs by offering lower prices in exchange for PBMs pressuring doctors to write those specific prescriptions. The following sections examine the five competitive forces that drive the pharmaceutical industry, as identified in Porter's Five Forces framework.
Supplier power exists when the pharmaceutical company supplying a medication controls market dynamics because of the volume of demand for that drug. Supplier power is shaped by many different aspects of selling a specified drug. Once a drug is released to market, the company must sell as much of it as possible to recoup the cost of development. In this initial phase, supplier power is defined by the price of the drug and the volume of sales achieved.
The threat of substitutes arises when a drug has been replicated. Once a comparable drug enters the market, the original company no longer holds supplier power and is forced to lower its price. Consumers must evaluate the substitute and choose the drug that offers the greatest benefits at an acceptable cost.
Buyer power is primarily defined by the choices available to buyers. When alternative drugs exist on the market, buyers generally have greater power. In markets with limited buyers and many producers, buyers can effectively set the price, shifting the balance of power away from the supplier.
Porter's Five Forces reveal the intense competitive pressures that shape the pharmaceutical industry at every level. These forces ultimately extend beyond company boardrooms, influencing the decisions of physicians and the care received by patients. Understanding supplier power, the threat of substitutes, buyer power, rivalry, and barriers to entry is essential for grasping how pharmaceutical markets function and how ethical and legal safeguards work to protect patients within that competitive environment.
You’re 50% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.